📊 This is a company profile preview from Tablestat.com Request a Free Trial Now

Company profile: Pherin

1.1 - Company Overview

Pherin Logo

Pherin

Headquarter: United States
Founded: 20XX🔒
Employees: 100-500🔒

Company description

  • Provider of clinical-stage investigational drugs for psychiatric and neurological disorders, particularly anxiety and depression, developing pherines (a new class of drugs) and an oral antagonist targeting the glycine site of the N-methyl-D-aspartate receptor (NMDAR). Privately held.

Products and services

  • Oral antagonist of the glycine site of the N-methyl-D-aspartate receptor (NMDAR): Investigational oral, receptor-targeted product that targets the NMDAR glycine site, intended for treating psychiatric and neurological disorders
  • Pherines: Clinical-stage investigational class engineered to treat psychiatric and neurological disorders, particularly anxiety and depression, representing a new drug category

Key contacts

🔒
🔒

Financial details

🔒

1.2 - Competitors and similar companies to Pherin

Embrella Cardiovascular Logo

Embrella Cardiovascular

HQ: United States Website
  • Description: Provider of a medical device system to enhance embolic cerebral protection, helping interventionalists reduce the frequency of embolic strokes during cardiovascular procedures; based in Malvern, Pennsylvania.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Embrella Cardiovascular company profile →
Convergence Pharmaceuticals Logo

Convergence Pharmaceuticals

HQ: United Kingdom Website
  • Description: Provider of novel analgesics for the treatment of chronic pain. An independent biotechnology company focused on developing therapies with potentially commercially attractive efficacy, responder-rate, and side effect profiles. Formed in October 2010 following the acquisition of certain neuroscience clinical assets from GlaxoSmithKline (GSK).
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Convergence Pharmaceuticals company profile →
Carbylan Logo

Carbylan

HQ: United States Website
  • Description: Provider of products and services; specific offerings not available. Founded in 2004.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Carbylan company profile →
Remedy Pharmaceuticals Logo

Remedy Pharmaceuticals

HQ: United States Website
  • Description: Provider of clinical-stage small molecule drug therapies for acute central nervous system disorders, developing treatments that target NCCa-ATP channels in traumatic brain injury, stroke, and spinal cord injury, including RP-1127, an intravenous glyburide inhibitor acting through type-1 sulfonylurea antagonism.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Remedy Pharmaceuticals company profile →
Sio Gene Therapies Logo

Sio Gene Therapies

HQ: United States Website
  • Description: Provider of clinical-stage biopharmaceutical solutions.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Sio Gene Therapies company profile →
🔒

2.M&A buyers

2.1 Potential strategic acquirers in the sector

🔒
🔒
🔒
🔒 View all strategic buyers with complete profiles
Start Free Trial →

2.2 - Strategic buyer groups for Pherin

🔒

Buyer group 1: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 2: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 3: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to Pherin

2.2 - Growth funds investing in similar companies to Pherin

🔒 View all growth equity funds with complete profiles
Start Free Trial →

4 - Top valuation comps for Pherin

4.2 - Public trading comparable groups for Pherin

🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →

4.3 - M&A Transactions similar to Pherin

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA
🔒 View all M&A transactions with complete deal terms
Request Free Trial Now →

Frequently Asked Questions

About Pherin

What does Pherin do?

Pherin is a provider of clinical-stage investigational drugs for psychiatric and neurological disorders, particularly anxiety and depression, developing pherines (a new class of drugs) and an oral antagonist targeting the glycine site of the N-methyl-D-aspartate receptor (NMDAR). Privately held.

Who are Pherin's competitors?

Pherin's competitors and similar companies include Embrella Cardiovascular, Convergence Pharmaceuticals, Carbylan, Remedy Pharmaceuticals, and Sio Gene Therapies.

Where is Pherin headquartered?

Pherin is headquartered in United States.

How many employees does Pherin have?

Pherin has 1,000 employees 🔒.

When was Pherin founded?

Pherin was founded in 2010 🔒.

What sector and industry vertical is Pherin in?

Pherin is in the Enterprise Software 🔒 sector and industry

M&A Buyers & Acquirers for Pherin

Who are the top strategic acquirers in Pherin's sector and industry

Top strategic M&A buyers and acquirers in Pherin's sector include ████████, ██████████, ██████, ████████, and ██████████ 🔒.

Which M&A buyer groups are most relevant for Pherin?

Top strategic M&A buyers groups and sectors for Pherin include █████████████████ , ████████████████, █████████████, ████████████, and ████████████████ 🔒.

Financial Investors investing in Pherin's sector and industry vertical

Which are the top PE firms investing in Pherin's sector and industry vertical?

Top PE firms investing in Pherin's sector and industry vertical include ████████, ██████████, ████████, and ██████████ 🔒.

Who are the top buyout funds acquiring in Pherin's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in Pherin's sector and industry vertical include █████████, ██████████, ████████████, and ████████████ 🔒.

Who are the top growth equity funds investing in companies in Pherin's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to Pherin include █████████, ██████████, ████████████, and ████████████ 🔒.

Valuation benchmarks of companies in Pherin's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for Pherin?

The key public trading comparables and valuation benchmarks for Pherin include █████████, ██████████, ████████████, and ████████████ 🔒.

Which are the key trading comparable groups for Pherin for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for Pherin with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in Pherin's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for Pherin with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in Pherin's' sector and industry vertical?

Access recent funding rounds and capital raises in Pherin's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for Pherin

Launch login modal Launch register modal